Sleep-Wake Signaling
Research has examined possible relationships between DSIP and the biological processes involved in sleep initiation and sleep patterns.
DSIP (Emideltide)
Emerging Research in Sleep and Neuroendocrine Regulation
What Is DSIP?
Delta Sleep-Inducing Peptide (DSIP), also known as Emideltide, is a naturally occurring peptide that has
been investigated for its potential role in sleep regulation and neuroendocrine signaling.
DSIP is a short peptide composed of nine amino acids. Since its discovery, researchers have explored its
relationship with sleep architecture, stress responses, circadian physiology, and other functions of the
central nervous system.
DSIP remains an investigational peptide, and its precise biological role in humans is not fully established.
Why Is DSIP Being Studied?
Researchers became interested in DSIP because early human studies suggested that administration of
synthetic DSIP could influence certain measures of sleep.
Small clinical studies have investigated DSIP in healthy volunteers and individuals experiencing chronic
insomnia. Some studies reported changes such as improved sleep efficiency, shorter sleep latency, or
changes in total sleep time.
However, the available studies are small, many were conducted decades ago, and results have not been
consistently reproduced in modern, large-scale clinical trials.
For these reasons, DSIP continues to be an area of scientific interest rather than an established treatment
for sleep disorders.
An investigational peptide
How Is DSIP Being Studied?
The biological role and mechanism of delta sleep-inducing peptide, or DSIP, remain unresolved. Early laboratory and clinical research has explored whether DSIP may participate in several interconnected signaling processes.
Circadian Processes
Early studies explored whether DSIP-related activity may vary with the body’s daily sleep and wake rhythms.
Neuroendocrine Activity
Investigators have studied possible connections with hormonal and nervous-system signaling.
Stress-Response Pathways
Preclinical research has considered whether DSIP may interact with physiologic responses associated with stress.
Central Nervous System Activity
Researchers continue to investigate possible effects involving neural signaling and sleep-related regulation.
Evidence context:
These are areas of investigation—not established clinical
benefits. Available human studies are small and largely older,
and they have not established the safety or clinical
effectiveness of DSIP. FDA has also reported insufficient
safety information for proposed routes of administration.
Areas of Research Interest
Sleep Quality and Sleep Architecture
DSIP has been investigated for its potential influence on sleep onset, sleep efficiency, total sleep time, nighttime awakenings, and different stages of sleep. Several small historical studies reported improvements in selected sleep measurements, while other controlled research found effects that were limited or of uncertain clinical significance. More rigorous contemporary research is necessary to determine whether DSIP meaningfully improves sleep.
Chronic Insomnia
DSIP has been studied experimentally in individuals with chronic insomnia. Some early studies reported improvements in sleep efficiency and sleep latency. However, the evidence remains limited, and DSIP should not be considered an established treatment for insomnia. Patients experiencing persistent insomnia should receive a comprehensive medical evaluation to identify possible contributors such as sleep apnea, hormonal abnormalities, medication effects, anxiety, depression, circadian disorders, or other medical conditions.
Neuroendocrine and Stress Research
Researchers have also explored the relationship between DSIP and neuroendocrine pathways involved in the body’s response to stress. These areas remain largely experimental, and additional human research is necessary before therapeutic conclusions can be made.
Other Neurologic Research
DSIP has historically been investigated in several additional neurologic and physiologic contexts. During the FDA’s 2026 evaluation of Emideltide-related bulk drug substances, the agency reviewed proposed uses involving chronic insomnia, narcolepsy, and opioid withdrawal. Evaluation of a substance for these purposes does not establish that DSIP is safe or effective for these conditions.
Potential Benefits Under Investigation
- Sleep regulation
- Sleep efficiency
- Sleep onset and continuity
- Healthy sleep architecture
- Circadian and neuroendocrine signaling
- Physiologic stress regulation
Important Limitations
- DSIP/Emideltide is not an FDA-approved drug for insomnia or other proposed therapeutic uses.
- Human clinical evidence is limited and largely consists of small, older studies.
- Published studies have produced mixed results.
- Optimal dosing, route of administration, treatment duration, and long-term safety have not been established.
- Potential drug interactions and contraindications have not been adequately characterized.
- Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or manufacturing quality before marketing.
- DSIP should not replace established evaluation or treatment of an underlying sleep disorder.
Safety considerations
Potential Risks and Limitations
Because high-quality human safety data are limited, the complete risk and adverse-effect profile of DSIP remains unknown. The following concerns should be discussed with a qualified medical provider.
Limited Human Safety Data
Available human studies are small and largely older, leaving both short- and long-term safety insufficiently characterized.
Potential Immune Responses
FDA has identified potential immunogenicity concerns for certain proposed routes of administration.
Product Quality and Impurities
Potential concerns include peptide aggregation, peptide-related impurities, and inconsistencies in active ingredient characterization.
Injection-Related Risks
When administered by injection, general risks can include discomfort, irritation, bruising, contamination, or infection.
Unpredictable Individual Response
Effects involving sleep patterns, alertness, or nervous-system activity have not been reliably characterized and may vary.
Interactions and Medical Conditions
Potential interactions with sedatives, other medications, and underlying medical conditions have not been adequately studied.
Important:
DSIP, also known as emideltide, is not FDA-approved as a treatment
for insomnia or other medical conditions. People who are pregnant
or breastfeeding, take sedating medications, or have significant
neurologic, psychiatric, or other medical conditions should not
self-administer DSIP and should speak with a qualified healthcare
provider.
Frequently Asked Questions
No. DSIP, also known as Emideltide, is not an FDA-approved drug for the treatment of insomnia, narcolepsy, opioid withdrawal, or other medical conditions. Emideltide-related bulk drug substances were evaluated by the FDA’s Pharmacy Compounding Advisory Committee in July 2026 as part of the process concerning substances nominated for potential inclusion on the Section 503A Bulks List. This regulatory review should not be confused with FDA approval of DSIP as a medication.
DSIP has been investigated for its potential role in sleep regulation, but it is not an FDA-approved sleeping medication. Its proposed effects appear different from conventional sedative-hypnotic medications, but its mechanisms and clinical effectiveness remain incompletely understood.
DSIP has been studied experimentally in people with insomnia, and some small studies reported improvements in selected measures of sleep. However, the evidence is insufficient to establish DSIP as a standard treatment for chronic insomnia.
DSIP stands for Delta Sleep-Inducing Peptide. Emideltide is another name used for the same nine-amino-acid peptide.
Researchers have studied DSIP’s effects on sleep architecture, but current evidence does not establish that DSIP reliably increases deep sleep or produces a specific improvement in sleep stages. Individual studies have reported different findings, and additional controlled research is needed.
Why Choose Alpha Hormones®?
Sleep problems can have many underlying causes, including hormonal changes, stress, lifestyle, medications, and other health conditions. At Alpha Hormones®, our clinicians take time to understand your symptoms, review your health, and recommend appropriate testing when needed. We’ll clearly explain your options and help determine whether peptide therapy may be right for you.
Selected References
-
1
FDA Pharmacy Compounding Advisory Committee: Emideltide-Related Bulk Drug Substances
FDA meeting materials from July 23–24, 2026, addressing Emideltide—also known as delta sleep-inducing peptide or DSIP—and its proposed compounded uses.
-
2
FDA Global Substance Registration System: Emideltide
FDA substance-identification record for Emideltide and DSIP. A UNII listing identifies a substance but does not imply FDA approval.
-
3
Effects of DSIP on Sleep in Chronic Insomnia: A Double-Blind Study
A small controlled human study that found limited changes in selected sleep measurements and concluded that short-term DSIP was unlikely to provide major therapeutic benefit.
-
4
The Influence of Synthetic DSIP on Disturbed Human Sleep
An early clinical investigation involving a small group of adults with chronic insomnia and selected measurements of sleep duration, interruptions, and sleep stages.
-
5
Delta Sleep-Inducing Peptide: A Still Unresolved Riddle
A peer-reviewed review discussing the uncertain biological role, proposed mechanisms, and limited evidence connecting DSIP with sleep regulation.
-
6
Acute and Delayed Effects of DSIP on Human Sleep Behavior
A small double-blind crossover study involving six healthy volunteers that examined immediate and delayed changes in sleep measurements after synthetic DSIP administration.
-
7
Delta Sleep-Inducing Peptide: An Update
A peer-reviewed review of early DSIP research involving sleep, pain, withdrawal, neuroendocrine activity, and proposed physiologic effects.
-
8
DSIP as a Tool for Investigating Sleep-Onset Mechanisms
A scientific review examining DSIP in relation to sleep onset, circadian activity, thermoregulation, cardiovascular signaling, and other proposed physiologic effects.
-
9
Effects of DSIP on Narcolepsy
A historical report involving a single patient with narcolepsy. Because this was an individual case rather than a controlled clinical trial, it cannot establish safety or effectiveness.
-
10
Opioid Detoxification With Delta Sleep-Inducing Peptide
An open clinical investigation of DSIP during opioid withdrawal. Its design and limited evidence do not establish DSIP as an effective withdrawal treatment.
-
11
Amino-Acid Sequence, Synthesis, and Experimental Activity of DSIP
Early preclinical research describing the peptide’s amino-acid sequence, laboratory synthesis, and effects on EEG activity in animal models.
-
12
Delta Sleep-Inducing Peptide: Scientific Review
A peer-reviewed overview of DSIP physiology and pharmacology, including its proposed relationship with sleep and other neurologic processes.
These references are provided for educational context. Regulatory review, substance registration, or publication of preliminary research does not establish that DSIP is FDA approved, safe, or effective for any medical condition.
Medical and Regulatory Disclaimer
DSIP (Emideltide) is an investigational peptide and is not FDA approved to diagnose, treat, cure, or prevent disease. The information on this page is educational and does not establish that DSIP is safe or effective for insomnia, narcolepsy, opioid withdrawal, or any other condition.
The regulatory and compounding status of peptides may change. Availability of any compounded preparation depends on applicable laws, pharmacy requirements, and an individualized clinical evaluation. A qualified healthcare professional should review the available evidence, potential risks, alternatives, medications, and existing medical conditions before any treatment decision.
